Published 2017
| Version v1
Publication
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
- Creators
- Belli, Valentina
- Sforza, Vincenzo
- Cardone, Claudia
- MARTINELLI, Erika
- Barra, Giusi
- Matrone, Nunzia
- Napolitano, Stefania
- MORGILLO, Floriana
- TUCCILLO, Concetta
- FEDERICO, Alessandro
- Dallio, Marcello
- LOGUERCIO, Carmelina
- Gravina, Antonietta Gerarda
- DE PALMA, Raffaele
- CIARDIELLO, Fortunato
- TROIANI, Teresa
- Others:
- Belli, Valentina
- Sforza, Vincenzo
- Cardone, Claudia
- Martinelli, Erika
- Barra, Giusi
- Matrone, Nunzia
- Napolitano, Stefania
- Morgillo, Floriana
- Tuccillo, Concetta
- Federico, Alessandro
- Dallio, Marcello
- Loguercio, Carmelina
- Gravina, Antonietta Gerarda
- DE PALMA, Raffaele
- Ciardiello, Fortunato
- Troiani, Teresa
Description
Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed.
Additional details
- URL
- http://hdl.handle.net/11567/999296
- URN
- urn:oai:iris.unige.it:11567/999296
- Origin repository
- UNIGE